This Website uses cookies to provide you with a personalized browsing experience. By using this Website, you agree to our use of cookies as explained in our Privacy Policy. Please read our Privacy Policy for more information on how we use cookies and how you can manage them.

Investor Information

Social responsibility has been at the core of Cipla, since inception. Cipla Foundation takes the company’s socially conscious legacy forward through initiatives in:

Explore »
A tiki taka approach of collaboration resulted in @Cipla_Global recording a strong growth in FY19. Our Quarterly Global Townhall concluded on an encouraging note - to sustain this purpose-driven momentum. What a great way to kick-start FY20! https://t.co/DodP1zGQgO
A tiki taka approach of collaboration resulted in Cipla recording a strong growth in FY19. Our Quarterly Global Townhall concluded on an encouraging note - to sustain this purpose-driven momentum. What a great way to kick-start FY20!
A tiki taka approach of collaboration resulted in Cipla recording a strong growth in FY19. Our Quarterly Global Townhall concluded on an encouraging note - to sustain this purpose-driven momentum. What a great way to kick-start FY20!
Cipla FY19 closes on a strong note, recording robust growth across markets. Watch @Vohra_Umang share how we continue to make huge strides in broadening our offerings to patients- through innovative products, health campaigns & digital healthcare solutions. https://t.co/LvVabulg6K
Cipla Q4 and FY19 Results Cipla FY19 closes on a strong note with India, South Africa, US and key emerging markets recording robust growth. Watch Umang Vohra share how we are well poised for FY20 and continue to make huge strides in broadening our offerings ...
@ashish64000 Hi, please DM us your contact details along with your location and the product batch number. Our team will assist you.
@mangesh35486882 Hi, please DM us your contact details along with your location and the product batch number. Our team will assist you.
Cipla is undergoing a big transformation and is doing something it once eschewed Steering Cipla onto a purpose-driven growth trajectory – Samina Vaziralli and @Umang Vohra share their vision of a future-ready #Cipla
A difficult transformation is underway at Cipla, one of Indias largest and oldest pharma companies.
Cipla receives final USFDA approval for generic version of Gilead Sciences, Inc’s Letairis® (Ambrisentan Tabs, 5mg & 10mg) for the treatment of pulmonary arterial #hypertension (PAH) http://bit.ly/2V6MZtM